NuProbe, a Houston, USA, Shanghai, China and Suzhou, China-based genomics and molecular diagnostics company specialized in ultrasensitive sequencing panels, closed a $42M funding round.

The round was led by BioTrack Capital and Yonghua Capital with participation from Taifu Capital, Panlin Capital, Juming Capital, and Tuobang Capital and previous investors Sequoia Capital China, Ruomu Capital, and Serica Partners.

The company intends to use the funds to expand the commercial team in both the US and China, develop new NGS products, and file for regulatory approval in China for NuProbe’s clinical products.

Led by Yingshuang Chai, co-founder and CEO, NuProbe is a genomics and molecular diagnostics company with molecular diagnostic technologies to improve the sensitivity of sequencing mutations and copy number variations by over 10-fold. In the past 12 months, NuProbe has signed a number of partnership and licensing deals with internationally renowned companies in molecular diagnostics and life sciences, including Illumina, Qiagen, Oxford Nanopore, and the Wego Group. The company has begun to partner with pharma companies for clinical research through its Augury™ custom NGS panels. In the reproductive health field in China, NuProbe has built collaborations with most of the top hospitals and is the leader in infertility testing.

The team also includes David Zhang, co-founder and Head of Innovation while the scientific advisory board includes David Walt and George Church.